Related Experiment Video
Updated: Aug 18, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate
J T van Leeuwen1, A J Smit, J F May
1Department of Internal Medicine, Groningen University Hospital, The Netherlands.
Insights
Lisinopril significantly reduced left ventricular mass index in hypertensive patients, while both lisinopril and diltiazem improved diastolic filling. Lisinopril also demonstrated superior 24-hour blood pressure control compared to diltiazem.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension leads to left ventricular (LV) remodeling, including increased LV mass and diastolic dysfunction.
- Effective antihypertensive treatment is crucial for improving cardiac structure and function.
Purpose of the Study:
- To compare the effects of diltiazem and lisinopril on LV mass and diastolic filling in untreated hypertensive patients.
- To assess the impact of these treatments on office and ambulatory blood pressure.
Main Methods:
- A 6-month randomized study involving 36 hypertensive patients.
- Echocardiography and pulsed Doppler were used to measure LV mass and diastolic filling parameters.
- Office and 24-hour ambulatory blood pressure monitoring were conducted.
Main Results:
- Lisinopril significantly decreased LV mass index compared to diltiazem (p < 0.05).
- Both drugs improved diastolic filling parameters, with no significant inter-group difference.
- Lisinopril showed greater reductions in daytime and nighttime ambulatory blood pressure compared to diltiazem (p < 0.05).
Conclusions:
- Lisinopril is effective in reducing LV mass in hypertensive patients.
- Both diltiazem and lisinopril improve diastolic function, but lisinopril offers better 24-hour blood pressure control.
- Improvements in diastolic filling may be influenced by factors beyond LV mass reduction.
Abstract:
The comparative effects on echocardiographically determined left ventricular (LV) mass and pulsed Doppler derived indexes of LV diastolic filling were studied in previously untreated hypertensive patients after 6 months of treatment with diltiazem 300 mg once daily (o.d.) (n = 16), and lisinopril 20 mg o.d. (n = 20). LV mass index decreased in the lisinopril group (from 98 to 96 g/m2; mean difference after 6 months of treatment with diltiazem-lisinopril was 13.7 g/m2 [95% confidence interval (CI) 0.8 to 26.6, p < 0.05]. In both groups diastolic filling parameters improved, but there was no statistically significant difference between the groups. Both treatment regimens showed a similar decrease in office and maximal exercise systolic blood pressure (SPB). Ambulatory daytime BP was lower after lisinopril treatment (from 147/96 to 126/83 mm Hg) than after diltiazem treatment (from 142/93 to 135/87 mm Hg); mean difference between diltiazem and lisinopril after 6 months of treatment was 9.7 (95% CI 3.4 to 16.0, p < 0.05)/9.4 (95% CI 2.5 to 16.3, p < 0.05) mm Hg. Nighttime BP decreased from 129/81 to 113/70 mm Hg in the lisinopril group, but not in the diltiazem group (from 125/79 to 122/77 mm Hg); mean difference between diltiazem and lisinopril after 6 months of treatment was 4.4 (95% CI - 0.2 to 8.9)/6.6 (95% CI 1.1 to 12.0) mm Hg. Changes in diastolic filling parameters were significantly correlated with changes in LV mass index in the lisinopril group, suggesting that the improvements in diastolic filling in the diltazem group may be partly due to an effect on factors other than LV mass.
More Related Videos
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
08:57Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease
Published on: May 22, 2026
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Heart Failure II: Pathophysiology